Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From <scp>FDA</scp> Adverse Event Reporting System
The authors declare no conflicts of interest. Data supporting this study are available upon reasonable request to the corresponding author.
Authors
- James Jacobs (ORCID: https://orcid.org/0000-0002-6375-5940)
- Duc V. Le (ORCID: https://orcid.org/0000-0001-7851-0869)
- Giang Huong Nguyen (ORCID: https://orcid.org/0009-0002-9440-4243)
- Trang M Nguyen (ORCID: https://orcid.org/0000-0002-3877-0989)
- David A. Wetter
- Tung S Tran
Institutions
- Mayo Clinic (US)
- Hanoi Medical University (VN)
- Vietnam National Children's Hospital (VN)
- Bassett Medical Center (US)
Publication Details
- Journal
- International Journal of Dermatology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1111/ijd.70082
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00